• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

    1.575 +0.045 (+2.94%)
    Streaming Delayed Price Updated: 9:48 AM EDT, Oct 9, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 33,895
    Open 1.540
    Bid (Size) 1.570 (3)
    Ask (Size) 1.580 (12)
    Prev. Close 1.530
    Today's Range 1.530 - 1.580
    52wk Range 1.100 - 16.10
    Shares Outstanding 35,937,937
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
     
    Via Benzinga

    Performance

    YTD
    -88.1%
    -88.1%
    1 Month
    -9.0%
    -9.0%
    3 Month
    +15.8%
    +15.8%
    6 Month
    +20.2%
    +20.2%
    1 Year
    -86.0%
    -86.0%

    More News

    Read More
    Get insights into the top gainers and losers of Friday's after-hours session.
    Via Chartmill
    Pliant Therapeutics Provides Update on BEACON-IPF
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
    From Pomerantz LLP
    Via GlobeNewswire
    Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
    Via Benzinga
    Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    What's going on in today's after hours session
    Via Chartmill
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future
    Via Benzinga
    This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
    Via Benzinga

    Frequently Asked Questions

    Is Pliant Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Pliant Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Pliant Therapeutics, Inc. - Common Stock trade on?
    Pliant Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Pliant Therapeutics, Inc. - Common Stock?
    The ticker symbol for Pliant Therapeutics, Inc. - Common Stock is PLRX on the Nasdaq Stock Market
    What is the current price of Pliant Therapeutics, Inc. - Common Stock?
    The current price of Pliant Therapeutics, Inc. - Common Stock is 1.575
    When was Pliant Therapeutics, Inc. - Common Stock last traded?
    The last trade of Pliant Therapeutics, Inc. - Common Stock was at 10/09/25 09:48 AM ET
    What is the market capitalization of Pliant Therapeutics, Inc. - Common Stock?
    The market capitalization of Pliant Therapeutics, Inc. - Common Stock is 56.60M
    How many shares of Pliant Therapeutics, Inc. - Common Stock are outstanding?
    Pliant Therapeutics, Inc. - Common Stock has 57M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.